Q32 Bio Inc.
NASDAQ:QTTBBiotechnology
Healthcare
$8.48 -1.70%
-$0.22 today
- Market cap
- $253.75M
- Beta
- -0.23
- P/E (TTM)
- 5.4
- EPS (TTM)
- $2.36
52W Low $1.35High $14.85
Volume 0.31M
Average 0.74M
Income Statement
Follow revenue through to earnings.
Revenue
$53.74M
FY 2025 · Annual
Operating Income
$16.90M
FY 2025 · Annual
Net Income
$29.82M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 33.97M | 6.65M | (6.65M) | 0 | 53.74M |
| Cost of Revenue | 9.54M | 2.6M | 499K | 487K | 391K |
| Gross Profit | 24.43M | 6.65M | (6.65M) | (487K) | 53.35M |
| Gross Margin | 71.9% | 100.0% | 100.0% | — | 99.3% |
| Research & Development | 93.09M | 35.81M | 31.73M | 48.14M | 19.16M |
| Selling, General & Admin | 27.29M | 10.06M | 9.88M | 17.47M | 17.68M |
| Operating Expenses | 120.38M | 45.88M | 41.6M | 65.61M | 36.44M |
| Depreciation & Amortization | 9.54M | 370K | 499K | 487K | 391K |
| EBITDA | (86.22M) | (38.86M) | (47.76M) | (45.3M) | 17.29M |
| EBITDA Margin | -253.8% | -584.2% | 718.0% | — | 32.2% |
| Operating Income | (95.95M) | (39.23M) | (48.26M) | (66.1M) | 16.9M |
| Operating Margin | -282.4% | -589.8% | 725.5% | — | 31.5% |
| Interest Income | 185K | 3.23M | 0 | 3.9M | 2.2M |
| Interest Expense | 0 | 0 | 0 | 300K | 1.1M |
| Other Income / Expenses | 185K | (3.52M) | (5.17M) | 18.39M | 12.92M |
| Income Before Tax | (95.76M) | (42.75M) | (53.43M) | (47.71M) | 29.82M |
| Pre-Tax Margin | -281.9% | -642.7% | 803.3% | — | 55.5% |
| Income Tax Expense | 0 | 62K | 318K | 21K | 0 |
| Net Income | (95.76M) | (42.81M) | (53.74M) | (47.73M) | 29.82M |
| Net Margin | -281.9% | -643.6% | 808.0% | — | 55.5% |
| EPS (Basic) | (31.18) | (13.42) | (16.70) | (5.12) | 2.42 |
| EPS (Diluted) | (31.18) | (13.42) | (16.70) | (6.58) | 2.42 |
| 3.07M | 3.19M | 3.22M | 12.2M | 12.3M | |
| 3.07M | 3.19M | 3.22M | 12.2M | 12.31M |
QTTB Earnings Waterfall · TTM
NASDAQ:QTTB · Revenue to Net Income
Key Ratios
EPS$2.66
Gross Margin25.0%
Net Margin26.9%
P/E Ratio-1.0
P/S Ratio0.2
Analysis
$53.7M of revenue converted into $33.2M of net income for the selected period. Gross margin is 25.0% and net margin is 26.9%, showing how much revenue survives after costs and taxes. EPS is $2.66, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| 8-K | Current report | Nov 4, 2026 | |
| 10-Q | Quarterly report | Nov 4, 2026 | |
| SC 13G | SC 13G filing | Oct 28, 2026 |
How much revenue does QTTB generate?
Q32 Bio Inc. (QTTB) reported $53.74M of revenue in fiscal 2025.
Is QTTB profitable?
Q32 Bio Inc. (QTTB) reported $29.82M of net income, with a net margin of 55.5%.
Continue the stock analysis
Jump to another research area for this company.